A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes
Trial · NCT02692716
Results by group68
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 68
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time From Randomisation to First Occurrence of a Major Adverse Cardiovascular Event (MACE) Composite Endpoint Consisting of: Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke | Oral Semaglutide | 61 | Participants | ||
| Time From Randomisation to First Occurrence of a Major Adverse Cardiovascular Event (MACE) Composite Endpoint Consisting of: Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke | Placebo | 76 | Participants | ||
Time From Randomisation to First Occurrence of an Expanded Composite Cardiovascular Endpoint Consisting of: Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke, UAP Requiring Hospitalisation or Hospitalisation for Heart Failure | Oral Semaglutide | 83 | Participants | ||
Time From Randomisation to First Occurrence of an Expanded Composite Cardiovascular Endpoint Consisting of: Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke, UAP Requiring Hospitalisation or Hospitalisation for Heart Failure | Placebo | 100 | Participants | ||
| Time From Randomisation to First Occurrence of Each of the Individual Components in the Expanded Composite Cardiovascular Endpoint | Oral Semaglutide | Cardiovascular death | 15 | Participants | |
| Time From Randomisation to First Occurrence of Each of the Individual Components in the Expanded Composite Cardiovascular Endpoint | Placebo | Cardiovascular death | 30 | Participants | |
| Time From Randomisation to First Occurrence of Each of the Individual Components in the Expanded Composite Cardiovascular Endpoint | Oral Semaglutide | Non-fatal myocardial infarction | 37 | Participants | |
| Time From Randomisation to First Occurrence of Each of the Individual Components in the Expanded Composite Cardiovascular Endpoint | Placebo | Non-fatal myocardial infarction | 31 | Participants | |
| Time From Randomisation to First Occurrence of Each of the Individual Components in the Expanded Composite Cardiovascular Endpoint | Oral Semaglutide | Non-fatal stroke | 12 | Participants | |
| Time From Randomisation to First Occurrence of Each of the Individual Components in the Expanded Composite Cardiovascular Endpoint | Placebo | Non-fatal stroke | 16 | Participants | |
| Time From Randomisation to First Occurrence of Each of the Individual Components in the Expanded Composite Cardiovascular Endpoint | Oral Semaglutide | Unstable angina requiring hospitalisation | 11 | Participants | |
| Time From Randomisation to First Occurrence of Each of the Individual Components in the Expanded Composite Cardiovascular Endpoint | Placebo | Unstable angina requiring hospitalisation | 7 | Participants | |
| Time From Randomisation to First Occurrence of Each of the Individual Components in the Expanded Composite Cardiovascular Endpoint | Oral Semaglutide | Heart failure requiring hospitalisation | 21 | Participants | |
| Time From Randomisation to First Occurrence of Each of the Individual Components in the Expanded Composite Cardiovascular Endpoint | Placebo | Heart failure requiring hospitalisation | 24 | Participants | |
| Time From Randomisation to First Occurrence of a Composite Endpoint Consisting of: All-cause Death, Non-fatal Myocardial Infarction or Nonfatal Stroke | Oral Semaglutide | 69 | Participants | ||
| Time From Randomisation to First Occurrence of a Composite Endpoint Consisting of: All-cause Death, Non-fatal Myocardial Infarction or Nonfatal Stroke | Placebo | 89 | Participants | ||
| Time From Randomisation to First Occurrence of Fatal or Non-fatal Myocardial Infarction | Oral Semaglutide | 37 | Participants | ||
| Time From Randomisation to First Occurrence of Fatal or Non-fatal Myocardial Infarction | Placebo | 35 | Participants | ||
| Time From Randomisation to First Occurrence of Fatal or Non-fatal Stroke | Oral Semaglutide | 13 | Participants | ||
| Time From Randomisation to First Occurrence of Fatal or Non-fatal Stroke | Placebo | 17 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02692716/results